Frontiers of Ultrasound Technology in Prostate Cancer Treatment
International Journal of Urology · 2025
DOI: 10.1111/iju.70160 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2025. Verfasst von Sunao Shoji und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokai University School of Medicine, Isehara, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Ultrasound, High-Intensity Focused, Transrectal, High-Intensity Focused Ultrasound Ablation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Focal therapy is a minimally invasive alternative treatment for localized prostate cancer (PC) aiming to achieve oncological control while preserving urinary and sexual functions. High‐intensity focused ultrasound (HIFU) and high‐intensity directional ultrasound (HIDU) enable precise prostate ablation guided by real‐time transrectal ultrasound or magnetic resonance imaging (MRI) fusion imaging. This review evaluates the current status and prospects of ultrasound technology in the treatment of PC. HIFU provides precise tumor ablation with minimal damage to the surrounding tissues, whereas HIDU allows MRI‐guided transurethral treatment with real‐time thermometry. Clinical studies have reported favorable biochemical recurrence‐free survival and functional outcomes. In Japan, a multi‐institutional prospective study on focal therapy using HIFU has been approved as an advanced medical technology by the Minister of Health, Labor, and Welfare. This study compared the oncological and functional outcomes of HIFU‐based focal therapy and radical prostatectomy in pair‐matched patients to evaluate the effectiveness of HIFU in treating localized PC. HIFU induces immunogenic cell death, releases tumor‐associated antigens, and reduces immunosuppressive cells. Low‐intensity focused ultrasound enhances tumor immunogenicity by promoting heat shock protein expression and CD8 + T cell activation. In conclusion, HIFU and HIDU offer effective focal therapy options for localized PC, and the immunomodulatory properties of HIFU and low‐intensity focused ultrasound may benefit advanced PC treatment. Future studies should optimize patient selection by developing advanced imaging technologies and predictive models capable of visualizing MRI‐invisible lesions and accurately detecting micro‐metastatic disease. Moreover, evaluating long‐term outcomes and exploring their combination with immunotherapy to enhance oncological efficacy will be essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Tokai University School of Medicine, Isehara, Japan.
ORCID-Profile: Sunao Shoji
Förderung
- Grants-in-Aid for Scientific Research (KAKENHI)
- Japan Society for the Promotion of Science
Zitieren
APA
Shoji, S., Takahashi, K., Naruse, J., & Kawamura, Y. (2025). Frontiers of Ultrasound Technology in Prostate Cancer Treatment. International Journal of Urology. https://doi.org/10.1111/iju.70160
Vancouver
Shoji S, Takahashi K, Naruse J, Kawamura Y. Frontiers of Ultrasound Technology in Prostate Cancer Treatment. International Journal of Urology. 2025. doi:10.1111/iju.70160
BibTeX
@article{Shoji2025,
author = {Shoji, Sunao and Takahashi, Kumpei and Naruse, Jun and Kawamura, Yoshiaki},
title = {Frontiers of Ultrasound Technology in Prostate Cancer Treatment},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70160}
}
EUVIMED